Results 201 to 210 of about 3,822 (260)

Efficacy and safety of recombinant activated factor VII in Glanzmann thrombasthenia: A systematic literature review. [PDF]

Haemophilia
Saultier P, Grino M, Falaise C, Voisin S, Lavenu-Bombled C, Ibrahim-Kosta M, Petit A, Boutroux H, Desprez D, Fiore M, d'Oiron R, Alessi MC.   +11 more
europepmc   +1 more source

<i>In vitro</i> derivation of megakaryocytes and platelets from induced pluripotent stem cells: developmental foundations and translational perspectives. [PDF]

Front Immunol
Mazurek M, Młynarski W, Grzela DP.
europepmc   +1 more source

Management challenge of a rare concomitant platelet glycoprotein IV/CD36 and IIb/IIIa deficiencies: Case illustration. [PDF]

Transfusion
Sekayan T, Allen ES, Kopko P, Stephens LD, Zhao M, Curtis BR, Sullivan MJ, Trapp-Stamborski V, von Drygalski A.   +8 more
europepmc   +1 more source

Clinical impact of Amotosalen and UV-A treatment (INTERCEPT™ Blood System) for platelet concentrate preparation in cardiac surgery. [PDF]

Blood Transfus
Mertes PM, Oulehri W, Gomis P, Malinovsky JM, Collange O, Audibert G, Kientz D, Levy F, Roche AC, Tacquard CA, Humbrecht C, Delabranche X.   +11 more
europepmc   +1 more source

Impact of HLA alloimmunization in gene-modified autologous stem cell transplant for transfusion-dependent thalassemia.

Blood
Gibson NM, Khandros E, Elgarten CW, Worster E, Monos DS, Thompson AA, Kwiatkowski JL, Olson TS.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Platelet transfusion: Alloimmunization and refractoriness

Seminars in Hematology, 2020
The transfusion of platelets for both prophylaxis and treatment of bleeding is relevant to all areas of medicine and surgery. Historically, guidance regarding platelet transfusion has been limited by a lack of good quality clinical trials and so has been based largely on expert opinion. In recent years however there has been renewed interest in methods
Catherine F. Prodger, Alexandros Rampotas, Lise J. Estcourt, Simon J. Stanworth, Michael F. Murphy   +4 more
openaire   +2 more sources

Platelet transfusion refractoriness and anti‐HLA immunization

Transfusion, 2021
AbstractPlatelet transfusion refractoriness (PTR), defined as an unsatisfactory post‐transfusion platelet count increment, is a common complication of patients receiving multiple transfusions. Different strategies are described in the management of PTR. In this work, we demonstrate the efficacy of the detection and identification of anti‐HLA antibodies
Blandin, Lucie, Dougé, Aurore, Fayard, Amandine, Bay, Jacques‐olivier, Berlie, Guillaume, Pereira, Bruno, Lemal, Richard, Rouzaire, Paul   +7 more
openaire   +2 more sources

Causes of refractoriness to platelet transfusion

Current Opinion in Hematology, 1995
Platelet refractoriness is a multifactorial problem that often leads to aggressive measures in an attempt to treat a thrombocytopenic patient. Identification of the underlying causes should allow for prevention and management regimens to improve both transfusion practice and patient outcome.
R C, Friedberg, P D, Mintz
openaire   +2 more sources

Platelet transfusions: The problem of refractoriness

Blood Reviews, 1990
Refractoriness is a complication of multiple platelet transfusions in 30-70% of patients with bone marrow failure. The major causes are HLA alloimmunisation and non-immune platelet consumption; the latter is usually found in patients with DIC, septicaemia or splenomegaly.
M F, Murphy, A H, Waters
openaire   +2 more sources

ABH antibodies causing platelet transfusion refractoriness

Transfusion, 1986
Two alloimmunized patients with multispecific anti‐HLA and high‐titered ABH antibodies showed transfusion failures after ABH‐mismatched HLA‐identical platelet transfusions, whereas ABH‐matched HLA‐identical platelets showed sufficient increments. The anti‐A and ‐B could be demonstrated on platelets by immunofluorescence tests using FITC‐labeled goat ...
A, Brand, K, Sintnicolaas, F H, Claas, J G, Eernisse   +3 more
openaire   +2 more sources